NCT05748938

A Study of RD14-01 in Patients With Advanced Solid Tumors

A Phase1/phase2，Single-arm, Open-label Study of RD14-01 in Patients With Advanced Solid Tumors

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 12 (estimated)
• Sponsor: 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the safety and tolerability of RD14-01, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ advanced solid tumors.

Detailed description

This single-arm, open-label, dose-escalation and dose-expansion study will evaluate the safety and tolerability of RD14-01, ROR1-targeting CAR T cells, in adults with ROR1+ advanced solid tumors.

Conditions

• Solid Tumor

Interventions

Type	Name	Description
BIOLOGICAL	RD14-01	ROR1 Targeted CAR-T cells

Timeline

• Start date: 2023-02-08
• Primary completion: 2024-08-08
• Completion: 2025-02-08
• First posted: 2023-03-01
• Last updated: 2023-03-01

Locations

1 site across 1 country: China